<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01732341</url>
  </required_header>
  <id_info>
    <org_study_id>STENTYS</org_study_id>
    <nct_id>NCT01732341</nct_id>
  </id_info>
  <brief_title>Stentys Coronary Stent System Clinical Trial in Patients With Acute Myocardial Infarction</brief_title>
  <acronym>APPOSITION V</acronym>
  <official_title>APPOSITION V: Stentys Coronary Stent System Clinical Trial in Patients With Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stentys</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stentys</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test compare the Stentys Stent with the Multi-Link Vision™ stent system&#xD;
      (Abbott Vascular Inc.)in patients with a heart attack. It is expected that the Stentys stent&#xD;
      is not worse than the Vision stent.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coronary artery disease continues to be the most common cause of morbidity and mortality in&#xD;
      the occidental world. Treatment of coronary atherosclerotic disease has been significantly&#xD;
      advanced by interventional cardiology, and in particular the advent of coronary arterial&#xD;
      stents. In comparison to angioplasty alone, stents have reduced the incidence of angiographic&#xD;
      as well as clinical restenosis, the recurrence of angina, the need for coronary arterial&#xD;
      bypass graft (CABG) surgery, the need for repeat revascularization and the occurrence of&#xD;
      major adverse cardiac events (MACE).However,problems remain due to failure to achieve optimal&#xD;
      stent apposition and normal myocardial reperfusion. Early stent malapposition may be due to&#xD;
      incomplete expansion or undersizing of balloon-expandable stents. Several studies have&#xD;
      emphasized the importance of early malapposition in the setting of ST elevation MI, in which&#xD;
      substantial thrombotic burden and the presence of diffuse vasoconstriction may be&#xD;
      contributory. The Stentys Coronary Stent System includes a self-expanding bare metal&#xD;
      (nitinol) stent on a rapid exchange (RX) delivery system. In view of the theoretical&#xD;
      implications of malapposition, the self-expanding property may offer a potential benefit.&#xD;
&#xD;
      This study is designed to evaluate the safety and effectiveness of the Stentys Coronary Stent&#xD;
      System in the treatment of de novo stenotic lesions in coronary arteries in patients&#xD;
      undergoing primary revascularization due to AMI as compared to the Multi-Link Vision™&#xD;
      coronary stent system (Abbott Vascular Inc. The study is powered for non-inferiority of the&#xD;
      Stentys Coronary Stent System compared to the Vision Stent System.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Decision to discontinue patient follow-up at 2 years.&#xD;
  </why_stopped>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target Vessel Failure</measure>
    <time_frame>12 months.</time_frame>
    <description>From date of randomization until the date of first documented TVF, assessed up to 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Stent Malapposition</measure>
    <time_frame>Immediately after procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">318</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>STENTYS self-apposing stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention to treat STEMI with the STENTYS self-apposing stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VISION balloon-expandable stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>STEMI treatment with a VISION balloon-expandable stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>STENTYS self-apposing stent</intervention_name>
    <description>Intervention to treat STEMI with the STENTYS self-apposing stent</description>
    <arm_group_label>STENTYS self-apposing stent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VISION balloon-expandable stent</intervention_name>
    <description>STEMI treatment with a VISION balloon-expandable stent&#xD;
--------------------------------------------------------------------------------</description>
    <arm_group_label>VISION balloon-expandable stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        General Inclusion Criteria&#xD;
&#xD;
          1. Subject ≥ 18 years old.&#xD;
&#xD;
          2. Subject experiencing clinical symptoms consistent with AMI of &gt;30 min. in duration.&#xD;
&#xD;
          3. ST elevation ≥1 mm in ≥2 contiguous leads or new left bundle branch block, or true&#xD;
             posterior MI with ST depression of ≥1 mm in ≥2 contiguous anterior leads.&#xD;
&#xD;
          4. Symptom duration is &lt;12 hours prior to signing informed consent.&#xD;
&#xD;
          5. Subject should be in catheterization laboratory and procedure started within 2 hours&#xD;
             of consent.&#xD;
&#xD;
          6. Patient provides written informed consent.&#xD;
&#xD;
          7. Patient agrees to all required follow-up procedures and visits.&#xD;
&#xD;
        Angiographic Inclusion Criteria&#xD;
&#xD;
          1. Based on coronary anatomy, PCI is indicated for the culprit lesion with anticipated&#xD;
             use of stenting.&#xD;
&#xD;
          2. The vessel diameter is either known or expected to be 2.5-4.0mm, without excessive&#xD;
             tortuosity or diffuse distal disease.&#xD;
&#xD;
          3. Lesion length ≥12mm and ≤ 23mm&#xD;
&#xD;
             -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General Exclusion Criteria&#xD;
&#xD;
          1. Currently enrolled in another investigational device or drug trial that has not&#xD;
             completed the primary endpoint or that clinically interferes with the current study&#xD;
             endpoints.&#xD;
&#xD;
          2. A previous coronary interventional procedure of any kind within 30 days prior to the&#xD;
             procedure.&#xD;
&#xD;
          3. Female patients of childbearing potential known to be pregnant.&#xD;
&#xD;
          4. Patients undergoing cardiopulmonary resuscitation.&#xD;
&#xD;
          5. Cardiogenic shock (SBP &lt;80 mmHg for &gt;30 minutes, or requiring IV pressors or emergency&#xD;
             IABP for hypotension).&#xD;
&#xD;
          6. The subject requires multivessel PCI at time of index procedure or any staged&#xD;
             procedure of the target vessel within 9 months or any non-target vessel within 30 days&#xD;
             post-procedure.&#xD;
&#xD;
          7. The target lesion requires treatment with a device other than PTCA prior to stent&#xD;
             placement (such as, but not limited to, directional coronary atherectomy, excimer&#xD;
             laser, rotational atherectomy, etc.). Thrombus aspiration may be used per operator&#xD;
             discretion.&#xD;
&#xD;
          8. Attempted thrombolysis.&#xD;
&#xD;
          9. Co-morbid condition(s) that could limit the subject's ability to participate in the&#xD;
             trial or to comply with follow-up requirements, or impact the scientific integrity of&#xD;
             the trial.&#xD;
&#xD;
         10. Concurrent medical condition with a life expectancy of less than 12 months.&#xD;
&#xD;
         11. Known left ventricular ejection fraction (LVEF) &lt; 25% at the most recent evaluation&#xD;
             (prior to the index hospitalization).&#xD;
&#xD;
         12. History of cerebrovascular accident or transient ischemic attack in the last 6 months.&#xD;
&#xD;
         13. Active peptic ulcer or active gastrointestinal (GI) bleeding.&#xD;
&#xD;
         14. History of bleeding diathesis or coagulopathy or inability to accept blood&#xD;
             transfusions.&#xD;
&#xD;
         15. Known hypersensitivity or contraindication to aspirin, heparin or bivalirudin,&#xD;
             clopidogrel or ticlopidine, cobalt, nickel, or sensitivity to contrast media, which&#xD;
             cannot be adequately pre-medicated.&#xD;
&#xD;
         16. Known serum creatinine level &gt; 2.5 mg/dl, eGFR &lt;30, or hemodialysis dependent.&#xD;
&#xD;
        Angiographic Exclusion Criteria&#xD;
&#xD;
          1. Unprotected left main coronary artery disease (obstruction greater than 60% in the&#xD;
             left main coronary artery that is not protected by at least one non-obstructed bypass&#xD;
             graft to the left anterior descending (LAD) or left circumflex (LCX) artery or a&#xD;
             branch thereof).&#xD;
&#xD;
          2. Multi-vessel intervention required during the index procedure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roxana Mehran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Sinai Hospital, New York NY</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maurice Buchbinder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fouyndation Cardiovascular Research, La Jolla, CA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Foundation Cardiovascular medicine</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>November 2, 2012</study_first_submitted>
  <study_first_submitted_qc>November 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2012</study_first_posted>
  <last_update_submitted>April 19, 2017</last_update_submitted>
  <last_update_submitted_qc>April 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>STEMI</keyword>
  <keyword>BMS</keyword>
  <keyword>Self-expanding stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

